1. Home
  2. MAIN vs VKTX Comparison

MAIN vs VKTX Comparison

Compare MAIN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Main Street Capital Corporation

MAIN

Main Street Capital Corporation

HOLD

Current Price

$56.27

Market Cap

4.8B

Sector

Finance

ML Signal

HOLD

VKTX

Viking Therapeutics Inc.

HOLD

Current Price

$28.77

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAIN
VKTX
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.0B
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
MAIN
VKTX
Price
$56.27
$28.77
Analyst Decision
Hold
Strong Buy
Analyst Count
7
7
Target Price
$61.57
$95.86
AVG Volume (30 Days)
394.2K
1.8M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
8.04%
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
N/A
N/A
Revenue This Year
$6.27
N/A
Revenue Next Year
$5.14
N/A
P/E Ratio
$61.32
N/A
Revenue Growth
N/A
N/A
52 Week Low
$48.95
$24.52
52 Week High
$65.85
$43.15

Technical Indicators

Market Signals
Indicator
MAIN
VKTX
Relative Strength Index (RSI) 44.02 30.44
Support Level $54.48 $26.47
Resistance Level $56.39 $35.36
Average True Range (ATR) 0.93 1.35
MACD -0.24 -0.46
Stochastic Oscillator 16.53 6.26

Price Performance

Historical Comparison
MAIN
VKTX

About MAIN Main Street Capital Corporation

Main Street Capital Corp is a principal investment firm focused on providing customized long-term debt and equity capital solutions to lower middle market ("LMM") companies and debt capital to private ("Private Loan") companies owned by or in the process of being acquired by a private equity fund. The group invests principally in secured debt investments, equity investments, warrants, and other securities of LMM companies, typically based in the U.S. The company operates as a single segment with a principal investment objective to maximize total return by generating current income from debt investments and current income and capital appreciation from equity and equity-related investments.

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Share on Social Networks: